← Leaderboards
Jaideep Behari
University Of Pittsburgh At Pittsburgh
$4,660,334
Attributed
$9,240,298
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,240,298 · 6
By mechanism
R01$3,678,371 · 1
UH3$2,306,928 · 1
UG3$1,540,594 · 1
K08$1,018,778 · 1
U01$695,627 · 2
Top collaborators
- Jian-Min Yuan6 shared
- Alejandro Soto-Gutierrez5 shared
- D. Lansing Taylor5 shared
- Laura E. Nagy1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Krystle Anne Frahm$1,647,529
- Ryan Lee Minster$6,529,066
- Mark T. Miedel$2,142,086
- Michael J. Jurczak$3,728,877
- Yuan Liu$4,548,206
Others in their field
Top investigators on “Liver”
- David Heimbrook · Leidos Biomedical Research, Inc.$183,557,534
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Richard Douglas Moore · Johns Hopkins University$59,048,354
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Michael S. Saag · University Of Alabama At Birmingham$50,288,385
- Mark A Kay · Stanford University$49,905,067
Research focus
LiverMetabolicLiver DiseasesLiver FibrosisAlcoholsInflammationFibrosisReceptorCirrhosisAdultMolecularObesityPhenotypeDiabetes MellitusHepatocyteGrowth And Development FunctionHigh RiskLipidsEnrollmentNon-Alcoholic Fatty Liver DiseaseHepaticAnimal ModelCytokineNonalcoholic Steatohepatitis
Grant awards (18)
Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health Outcomes$897,025
R01 · FY2025 · CA
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease$777,501
UH3 · FY2024 · TR
Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health Outcomes$628,176
R01 · FY2024 · CA
Differential risk factors for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease (MASLD) patients of native Hawaiians compared with US whites$235,817
R01 · FY2024 · CA
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease$762,142
UH3 · FY2023 · TR
Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health Outcomes$662,119
R01 · FY2023 · CA
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease$767,285
UH3 · FY2022 · TR
Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health Outcomes$620,404
R01 · FY2022 · CA
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 7/9$344,100
U01 · FY2022 · AA · contact PI
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease$791,956
UG3 · FY2021 · TR
Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health Outcomes$634,830
R01 · FY2021 · CA
Alcoholic Hepatitis Consortia: an intramural/extramural collaboration to unravel genetic determinants$351,527
U01 · FY2021 · AA
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease$748,638
UG3 · FY2020 · TR
Role of Beta-Catenin in the Molecular Pathogenesis of Alcoholic Steatohepatitis$207,045
K08 · FY2012 · AA · contact PI
Role of Beta-Catenin in the Molecular Pathogenesis of Alcoholic Steatohepatitis$208,202
K08 · FY2011 · AA · contact PI
Role of Beta-Catenin in the Molecular Pathogenesis of Alcoholic Steatohepatitis$205,548
K08 · FY2010 · AA · contact PI
Role of Beta-Catenin in the Molecular Pathogenesis of Alcoholic Steatohepatitis$201,135
K08 · FY2009 · AA · contact PI
Role of Beta-Catenin in the Molecular Pathogenesis of Alcoholic Steatohepatitis$196,848
K08 · FY2008 · AA · contact PI